Zydus Cadila has received tentative approval from the US Food and Drug Administration (FDA) to market Pimavanserin tablets, 10 mg (US RLD: Nuplazid tablets), the company said in a statement today.
It notified that the tablets are used to treat the symptoms of a certain mental/mood disorder (psychosis) that might occur with Parkinson’s disease. It helps lessen symptoms such as seeing or hearing things that are not there (hallucinations) and false beliefs (delusions)
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad, the statement concluded.